Major protease inhibitor triple combination trial begins soon: CD4 under 200, AZT experienced, 3TC naive.
James
J S
JS
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D004359:Drug Therapy, Combination; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D019259:Lamivudine; D016047:Zalcitabine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use*; D015215:Zidovudine / Q000008:administration & dosage / Q000627:therapeutic use*
D000998:Antiviral Agents; D017320:HIV Protease Inhibitors; D019259:Lamivudine; D015215:Zidovudine; D016047:Zalcitabine